We report a study on the importance of factor IX activation in thromboplastin-dependent coagulation in plasma. Diluted, CaCl2-containing thromboplastin solutions at constant phospholipid concentration were used to trigger the coagulation in plasma from patients with congenital factor IX and factor VIII deficiency in the presence and absence of added factors IX and VIII, and the generation of th...

Background Bone marrow transplantation (BMT)is nowadays used in various hematological disorders including leukemias. Hemophilia A & B are sex linked bleeding disorders in which there are various genetic abnormalities in factor VIII & IX genes. Among various hematological disorders, bleeding disorders mainly hemophilia in now widely treated using plasma derived and recombinant factor VIII & IX ...

background bone marrow transplantation (bmt)is nowadays used in various hematological disorders including leukemias. hemophilia a & b are sex linked bleeding disorders in which there are various genetic abnormalities in factor viii & ix genes. among various hematological disorders, bleeding disorders mainly hemophilia in now widely treated using plasma derived and recombinant factor viii & ix c...

development of inhibitor to factor viii is the most serious complication of hemophilia therapy. to determine the prevalence of inhibitors in iran hemophilia a patients exposed to blood products, 1280 hemophilia a patients (age range 9 months-84 years) were evaluated. all patients received several blood products such as fresh frozen plasma (ffp), cryoprecipitate, and factor viii. 635 of 1280 pat...

R a Abstract. Production of factor VIII or factor IX inhibitors is a major complication limiting the efficiency of substitutive therapy in haemophiliacs. Moreover, viral infections, the second serious complication of replacement therapy, may be associated to the occurrence of antiphospholipid antibodies which paradoxically lead to thrombosis. We investigated the prevalence of coagulation inhibi...

A chromogenic factor IX assay is developed which requires only two timedependent steps. Diluted plasma is mixed with a reagent containing factors VIII and X. The reaction is started by addition of a reagent containing factor XI", thrombin, CaCl2, and phospholipids. Then factor XIu activates factor IX if present, thrombin activates factor VIII, and subsequently the complete factor X activating c...

I NHIBITORS to factor VIII develop in approximately 1 5% of patients with hemophilia with an incidence of approximately 8 per 1,000 patient-years of observation.’ Clinically, these can be divided into high response inhibitors, which exhibit an anamnestic response after exposure to factor VIII, and low response inhibitors, which do not exhibit significant anamnesis.2 Because of their neutralizin...

based on epidemiologic data, women who take oral contraceptives seem to have an increased risk of developing thromboembollic disease. the thrombotic effects of oral contraceptive (oc) are probably mediated, at least partly through their effects on the coagulation system. plasma levels of several clotting factors have been shown to be elevated in oc users, and this increase is graduated accordin...

Up to 30% of haemophilia A patients and up to 3% of haemophilia B patients develop neutralizing antibodies (inhibitors) to factor VIII or factor IX, rendering replacement therapies ineffective and making the management of bleeding episodes particularly challenging.1–3While patients with low titre inhibitors may benefit from higher doses of factors VIII or IX, patients with higher antibody level...